In women with trophoblastic disease or hyperemesis gravidarum, hyperthyroidism due to chorionic gonadotropin (hCG) hypersecretion is commonly identified1'2. In men with hCG-secreting tumours, however, it seems to be rare3-5. We report such a case.
CASE HISTORY
A previously fit 33-year-old man reported abdominal discomfort, backache, anorexia, nausea, vomiting and weight loss. He had a pulse rate of 104 beats per minute and a central abdominal mass. Chest X-ray and ultrasound and computed tomography scans were consistent with metastatic disease involving the lungs, liver and para-aortic lymph nodes. There was no clinical or radiological testicular abnormality. A biopsy of the para-aortic lymph nodes was characteristic of embryonal carcinoma. Serum ,BhCG was 880 000 IU/L (reference range <4). Courses of bleomycin, etoposide and cisplatin monthly for four months led to resolution of symptoms; there was shrinkage of the paraaortic lymphadenopathy and lung metastases and serum PhCG fell to a nadir of 59 100 IU/L. When his fifth course of chemotherapy was postponed because of mild renal impairment, his condition deteriorated rapidly with dyspnoea, anorexia, vomiting and weight loss. He also developed tachycardia, hepatomegaly and gynaecomastia. A rise in serum #hCG confirmed tumour relapse. At this time he had a raised free thyroxine (72.4 pmol/L) and, unusually, a detectable level of thyroid stimulating hormone (TSH). Further investigations confirmed hyperthyroidism, but a different TSH immunoassay gave a suppressed result. The patient died and necropsy was not performed, but thyroid hormones and TSH were measured retrospectively. At presentation he had biochemical evidence of hyperthyroidism which, apart from a suppressed TSH (Amerlite) of <0.05 mU/L, reverted to normal after anti-tumour chemotherapy, but then recurred with tumour relapse (Table 1) . COMMENT Symptomless hyperthyroidism in men may go unrecognized if it resolves with successful cancer chemotherapy4. Why frank thyrotoxicosis does not always develop in hCGinduced hyperthyroidism is unknown but it may be that rapid tumour growth and hCG-induced thyroid hypersecretion outpaces the effects of thyroid hormone on the tissues.
In our patient, the reversal of hyperthyroidism by tumour chemotherapy and the later development of frank hyperthyroidism following tumour relapse is consistent with the notion that the tumour was causal in the development of hyperthyroidism. The likeliest thyroid stimulator is hCG but this is controversial6. hCG exists as different isoforms, and one suggestion is that desialated variants (produced more abundantly in patients with hCG-induced hyperthyroidism) have greater thyrotropic activity than sialated isoforms7'8
Although patients with hCG-induced hyperthyroidism may present with features typical of thyrotoxicosis, the commonest, and often. the only, presenting sign is tachycardia3-5. Other features of hCG-induced hyperthyroidism include extraordinarily high hCG and oestrogen concentrations, detectable serum 'TSH' levels (probably due to cross-reactivity of very high hCG levels in some TSH immunoassays), gynaecomastia and presence of metastatic disease3-5. Since hCG activity directly correlates with the number of tumour cells present, it is not surprising that high hCG levels reflect widespread and often terminal metastatic disease. 
